

**Amendments To The Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:


**In the Claims:**

What is claimed is:

1. (Original) A method for preparing dosage forms comprising low dose pharmaceutically active substances which comprises admixing carrier particles with a solution comprising the pharmaceutically active substance together with a binder therefor.
2. (Original) A method according to Claim 1 wherein the dose of pharmaceutically active substance is less than 100  $\mu\text{g}$ .
3. (Original) A method according to Claim 2 wherein the dose of pharmaceutically active substance is less than 20  $\mu\text{g}$ .
4. (Original) A method according to Claim 3 wherein the dose of pharmaceutically active substance is less than 1  $\mu\text{g}$ .
5. (Currently Amended) A method according to ~~Claims 1—4~~ claim 1 wherein the ratio of solution comprising drug and binder: carrier is 5 – 50:100.
6. (Original) A method according to Claim 5 wherein the ratio of solution comprising drug and binder: carrier is 15 – 35:100.
7. (Original) A method according to Claim 6 wherein the ratio of solution comprising drug and binder: carrier is 20 – 30:100.

8. (Currently Amended) A method according to ~~any preceding~~ claim 1 wherein the dosage form has a desired content uniformity of <7.5% RSD.
9. (Original) A method according to Claim 8 wherein the dosage form has a desired content uniformity of <6% RSD.
10. (Original) A method according to Claim 9 wherein the dosage form has a desired content uniformity of <3% RSD.
11. (Currently Amended) A method according to ~~Claims 1—10~~ claim 1 wherein the dosage form is a solid dosage form.
12. (Currently Amended) A method according to ~~Claim 1—11~~ claim 1 wherein the mixing step is carried out in a High Shear Mixer.
13. (Currently Amended) A method according to ~~any preceding~~ claim 1 wherein the mixture is formulated into unit dosage presentations.
14. (Currently Amended) A pharmaceutical composition comprising a drug obtainable by the ~~process~~ method of ~~any preceding~~ claim 1.

15. (Currently Amended) A method according to ~~any claim 1-13~~ claim 1 wherein the pharmaceutically active substance is Compound (1) (2-methyl-2-[4-[[4-methyl-2-[4-trifluoromethylphenyl]-thiazol-5-ylcarbonyl)amino]methyl]phenoxy] propionic acid )



Compound (1)

- or a pharmaceutically acceptable salt[[s]], solvate[[s]] ~~and~~ or physiologically functional derivative[[s]] thereof.
16. (Original) A pharmaceutical composition comprising 1-100 µg of Compound (1) or pharmaceutically acceptable salts, solvates and hydrolysable esters thereof together with a pharmaceutically acceptable carrier.
17. (Original) A pharmaceutical composition comprising less than 20 µg of Compound (1) or pharmaceutically acceptable salts, solvates and physiologically functional derivatives thereof together with a pharmaceutically acceptable carrier.
18. (Original) A pharmaceutical composition comprising 1-18 µg of Compound (1) or pharmaceutically acceptable salts, solvates and physiologically functional derivatives thereof together with a pharmaceutically acceptable carrier.

19. (Original) A pharmaceutical composition comprising 1-10  $\mu\text{g}$  of Compound (1) or pharmaceutically acceptable salts, solvates and physiologically functional derivatives thereof together with a pharmaceutically acceptable carrier.
20. (Original) A pharmaceutical composition according to ~~Claims 16-19~~ claim 16 wherein Compound (1) or pharmaceutically acceptable salts, solvates or physiologically functional derivatives thereof comprises form 2, form 6 and mixtures thereof.
21. (Original) A method of treatment of a human PPAR mediated disease or condition comprising administration to a subject a daily dose of 1-100  $\mu\text{g}$  Compound (1) or pharmaceutically acceptable salts, solvates and physiologically functional derivatives thereof.
22. (Original) A method according to Claim 21 wherein the daily dose of Compound (1) ) or pharmaceutically acceptable salts, solvates and physiologically functional derivatives thereof is less than 20 $\mu\text{g}$ .
23. (Original) A method according to Claim 22 wherein the daily dose of Compound (1) ) or pharmaceutically acceptable salts, solvates and physiologically functional derivatives thereof is 1-18 $\mu\text{g}$ .
24. (Original) A method according to Claim 23 wherein the daily dose of Compound (1) ) or pharmaceutically acceptable salts, solvates and physiologically functional derivatives thereof is 1-10 $\mu\text{g}$ .

25. (Currently Amended) A method according to ~~Claim 21-24~~ claim 21 wherein ~~where~~ Compound (1) comprises form 2, form 6 or mixtures thereof.

Claims 26-30 (Cancelled)

31. (Currently Amended) ~~Use of a~~ A method according to ~~claims 21-30~~ claim 21 wherein the Human (h) PPAR mediated diseases or conditions include dyslipidemia including associated diabetic dyslipidemia and mixed dyslipidemia, syndrome X (as defined in this application this embraces metabolic syndrome), heart failure, hypercholesteremia, cardiovascular disease including atherosclerosis, arteriosclerosis, and hypertriglyceridemia, type II diabetes mellitus, type I diabetes, insulin resistance, hyperlipidemia, inflammation, epithelial hyperproliferative diseases including eczema and psoriasis and conditions associated with the lung and gut and regulation of appetite and food intake in subjects suffering from disorders such as obesity, anorexia bulimia, and anorexia nervosa, cancer, Alzheimers disease or other cognitive disorders.